Form 4: Generation Bio Co. Executive Kevin John Conway Reports Stock Transactions

Kevin John Conway, Chief Financial Officer of Generation Bio Co., reports the vesting and disposal of restricted stock units.

Summary

• On January 15, 2025, Kevin John Conway, the Chief Financial Officer of Generation Bio Co., executed transactions involving the company's common stock.
• Conway vested 587 restricted stock units (RSUs) which converted into common stock.
• He then disposed of 204 shares of common stock at a price of $0.888 per share.
• Following these transactions, Conway directly owns 17,445 shares of Generation Bio Co. common stock and 4,694 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions, with no inherent positive or negative sentiment. It reflects standard executive compensation practices.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, common in publicly traded companies.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
• The vesting schedule of these RSUs is fairly standard, with an initial vesting cliff followed by quarterly installments.
• Similar companies such as CRISPR Therapeutics and Editas Medicine also utilize stock-based compensation for their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of the executive's compensation package.
• Shareholders may view the transactions as a routine part of executive compensation.

Key Dates